Related Experiment Video
Updated: Aug 14, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Polypharmacy in cardiorenal syndrome patients
Insights
Cardiorenal syndrome (CRS) involves complex heart and kidney interactions, often leading to polypharmacy. This paper explores strategies to reduce medication burden and improve adherence in CRS patients for better outcomes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Cardiorenal syndrome (CRS) describes intricate interactions between cardiac and renal dysfunction.
- CRS affects one-third of heart failure patients and is linked to poor clinical outcomes.
- Polypharmacy, using five or more medications, is prevalent in CRS and worsens outcomes.
Purpose of the Study:
- To highlight strategies for preventing polypharmacy in Cardiorenal Syndrome.
- To improve medication compliance and adherence in patients with CRS.
- To address the risks associated with polypharmacy in complex chronic conditions.
Main Methods:
- Review of existing literature on Cardiorenal Syndrome and polypharmacy.
- Identification of interventions such as deprescribing and multidisciplinary care coordination.
- Exploration of adherence-improving strategies including specialized clinics and telemonitoring.
Main Results:
- Polypharmacy is a significant issue in CRS, increasing with comorbidities.
- High medication burden in CRS patients is associated with poorer health and non-compliance.
- Various interventions show promise in mitigating polypharmacy risks.
Conclusions:
- Effective management of CRS requires addressing polypharmacy.
- Multidisciplinary approaches and patient-centered interventions are crucial for improving medication adherence.
- Strategies like deprescribing and telemonitoring can enhance patient outcomes in CRS.
Abstract:
Cardiorenal syndrome (CRS) is a term defined as complex interactions between concomitant cardiac and renal dysfunction in which disease of one organ initiates, perpetuates, and/or accelerates the decline in the other. It accounts for a third of presentations with heart failure and is associated with poor clinical outcomes. Polypharmacy (defined as using five or more medications) is common in CRS patients and is associated with worst clinical outcomes. The risk for polypharmacy increases to several fold with associated comorbidities, poses risks to the overall health of the patient, and enhances non-compliance to essential medications. Deprescribing non-essential medications, coordination between multiple specialties to mitigate the risk of polypharmacy, pharmacist- and nurse-led clinics to improve adherence to medications, use of polypills and telemonitoring are various methods to reduce polypharmacy. In this paper, we highlight different strategies to prevent polypharmacy and improve compliance and adherence to essential medications.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:22Heart Failure VI: Adjunct Therapies
01:29Cardiomyopathy V: Interprofessional Care
01:28Chronic Kidney Disease III: Interprofessional Care